Q32 Bio Inc. — Director's Dealing 2020

Dec 17, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2020-12-14

Reporting Person: 5AM Ventures IV, L.P. (10% Owner)
Reporting Person: 5AM Co-Investors IV, L.P. (10% Owner)
Reporting Person: 5AM Partners IV, LLC (10% Owner)
Reporting Person: DIEKMAN JOHN D (10% Owner)
Reporting Person: ROCKLAGE SCOTT M (10% Owner)
Reporting Person: Schwab Andrew J. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-14	Common Stock	S	151138	$13.0609	Disposed	5163346	Indirect
2020-12-14	Common Stock	S	328862	$11.88	Disposed	4834484	Indirect
2020-12-14	Common Stock	S	6297	$13.0609	Disposed	215138	Indirect
2020-12-14	Common Stock	S	13703	$11.88	Disposed	201435	Indirect

Footnotes

F1: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

F2: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.